

# AMB116457: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

Published: 14-08-2013

Last updated: 22-04-2024

Primary: to assess the longterm safety and tolerability of ambrisentan 5mg in subjects with inoperable CTEPH. Secondary: to collect supportive efficacy data.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Pulmonary vascular disorders
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON38441

### Source

ToetsingOnline

### Brief title

AMB116457

### Condition

- Pulmonary vascular disorders

### Synonym

chronic thromboembolic pulmonary hypertension; CTEPH

### Research involving

Human

## Sponsors and support

**Primary sponsor:** GlaxoSmithKline BV

**Source(s) of monetary or material Support:** GlaxoSmithKline BV

## Intervention

**Keyword:** ambrisentan, hypertension, pulmonary, thromboembolic

## Outcome measures

### Primary outcome

Adverse events.

### Secondary outcome

6 minute walk test, WHO functional class, Borg CR10 scale, clinical worsening of CTEPH, co-medication, NT-proBNP, SF-36 questionnaire.

## Study description

### Background summary

Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition characterized by thrombus organization, stenosis of pulmonary artery, and subsequent vascular remodeling in small unobstructed vessels, resulting in increased pulmonary vascular resistance, progressive pulmonary hypertension (PH) and right heart failure. CTEPH is associated with considerable morbidity and mortality.

The preferred treatment for CTEPH is surgical disobliteration of the arteries by pulmonary endarterectomy. The perioperative mortality is 5 to 10%. There are significant improvements in hemodynamics. However for some patients surgery is not an option. Management of these patients was previously supportive.

Disease-modifying therapies used in other forms of pulmonary arterial hypertension have been utilized. There are no licensed treatments for CTEPH. Ambrisentan is a selective endotheline receptor antagonist licensed for the treatment of WHO FC II and III PH. Given that the histopathologic changes seen in CTEPH, the evidence that endothelin-1 levels are raised, and the clinical evidence (mainly uncontrolled) that a number of licensed PH treatments show efficacy in CTEPH, it is hypothesised that ambrisentan may provide benefit to patients with inoperable CTEPH.

This is an open-label extension study of the placebo controlled phase III study

with ambrisentan in inoperable patients with CTEPH (AMB115811).

## **Study objective**

Primary: to assess the longterm safety and tolerability of ambrisentan 5mg in subjects with inoperable CTEPH.

Secondary: to collect supportive efficacy data.

## **Study design**

Open label, long term extension to study AMB115811. Ambrisentan 5 mg daily.

All subjects may continue in the extension study until one of the following conditions is met:

- \* The product is approved locally and made commercially available for use in inoperable CTEPH patients;
- \* Development for use in the CTEPH population is discontinued or product is not approved by the local regulatory authorities
- \* The investigator decides to discontinue the subject or subject decides to discontinue from the study.

## **Intervention**

Treatment with ambrisentan.

## **Study burden and risks**

Risk: Adverse effects of study medication.

Burden:

Monthly visits with blood draw (approx. 10 ml/occasion).

Every 3 months: Urine test, pregnancy test, physical examination, 6 minute walk test.

ECG every 6 months.

SF-36 questionnaire every 3 months during 1st 18 months.

## **Contacts**

### **Public**

GlaxoSmithKline BV

Huis ter Heideweg 62

Zeist 3705 LZ

NL

### **Scientific**

GlaxoSmithKline BV

Huis ter Heideweg 62  
Zeist 3705 LZ  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

\* Male and female patients with inoperable CTEPH, who have completed the week 16 visit of AMB115811 or who prematurely withdrew for whatever reason. Capable of giving informed consent.

### Exclusion criteria

\* Pregnancy or breastfeeding. Non compliance with contraceptive measures from AMB115811.

\* Subjects who are to enter another clinical trial or be treated with another investigational product after exiting Study AMB115811.

## Study design

### Design

Study phase: 3

Study type: Interventional

Masking: Open (masking not used)

Control:	Uncontrolled
Primary purpose:	Treatment

## Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	10-07-2014
Enrollment:	5
Type:	Actual

## Medical products/devices used

Product type:	Medicine
Brand name:	Volibris
Generic name:	ambrisentan
Registration:	Yes - NL outside intended use

## Ethics review

Approved WMO	
Date:	14-08-2013
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	16-12-2013
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	11-02-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	31-07-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	

Date: 03-04-2015  
Application type: Amendment  
Review commission: METC Amsterdam UMC

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
EudraCT	EUCTR2012-001642-17-NL
CCMO	NL45342.029.13
Other	www.clinicaltrials.gov; registratienummer n.n.b.